Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Global rights of the ongoing development have been licensed-in from Dutch company, QliniQ, who maintains the rights to commercialize the product candidate in its home country, and a selected number of Middle Eastern and developing countries.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 20, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Hyloris Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Clearmind Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The patent application is the third collaboration, each referring to the combination of SciSparc's Palmitoylethanolamide (PEA), the active ingredient of CannAmide™ and Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 22, 2022
Lead Product(s) : Palmitoylethanolamide,5-Methoxy-2-Aminoindane
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Clearmind Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Partnership
Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
Details : Cronos has successfully achieved the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid hypothesized to reduce the appetite-enhancing property of THC.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
June 21, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Ginkgo Bioworks
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Baymedica
Deal Size : Not Applicable
Deal Type : Not Applicable
InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector
Details : delta 9-dominant tetrahydrocannabivarin, d9-THCV is the naturally-occurring variant found in the Cannabis plant, to create unique health and wellness products.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 09, 2022
Lead Product(s) : Tetrahydrocannabivarin
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Baymedica
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Undisclosed
Sponsor : Boxcar PMJ
Deal Size : $20.0 million
Deal Type : Series A Financing
Immuneering Raises $20 Million in Oversubscribed Series A Funding
Details : Proceeds from the financing will be used to accelerate Immuneering’s pipeline including programs in cancer cachexia, next-generation KRAS inhibition and the RAF-MEK pathway.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
January 22, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Undisclosed
Sponsor : Boxcar PMJ
Deal Size : $20.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?